Citizens lowered the firm's price target on Pharvaris to $74 from $75 and keeps an Outperform rating on the shares. The Phase 3 CHAPTER-3 readout in Q3 is the next major catalyst, and if deucrictibant XR replicates its Phase 2 85% attack reduction, it could become a differentiated oral prophylactic for hereditary angioedema, while strong RAPIDe-3 data further de-risk the acute program and support substantial commercial potential across both indications, the analyst tells investors in a research note.
